Home Page Biographical Sketch Awards & Distinctions Intellectual Property Advisory 
Boards		 Invited Presentations National & International Activities Publications List & Index Books



Thomas Tobin
Invited Presentations, Seminars, Selected Educational Submissions, Epert Opinions, and Related Activities

Thomas Tobin has presented over 400 invited presentations worldwide.

  1. Ligand Binding Studies on Na++K+-ATPase, Department of Biochemistry, Michigan State University, Fall 1971.
  2. The Cardiac Glycosides and the Na++K+-ATPase, Department of Chemistry, Michigan State University, Spring 1972.
  3. First Int’l Symposium on the Na++K+-ATPase, New York Academy of Sciences Symposium, November 1973.
  4. Ontario Veterinary Association Conference on Anesthesia in Lab Animal Medicine, Toronto, January 1974.
  5. Neurochemistry Session Chairman, FASEB, Spring Meeting, Atlantic City, New Jersey, April 1974.
  6. Cardiac Glycosides, Erythrophleum Alkaloids and the Na++K+-ATPase, Physiology Institute, University of Aarhus, Denmark, September 1974.
  7. Erythrophleum Alkaloids and the Na++K+-ATPase, The Biochemical Society, Galway, Ireland, September 1974.
  8. Cardiac Glycoside Inhibition of Na++K+-ATPase: Its relation to their Ionotropic Actions, Department of Veterinary Science, University of Kentucky, October 1974.
  9. Cardiac Glycosides, Erythrophleum Alkaloids and the Na++K+-ATPase, Medical College of Pennsylvania, Department of Pharmacology, December 1974.
  10. Int’l Conference on Doping Research and Control, Paris, France, May 1975.( First ICRAV!)
  11. Cardiac Glycosides and the Na++K+-ATPase, Department of Pharmacology, University of Kentucky, September 1975.
  12. The Pharmacology of Procaine in the Horse and Its Forensic Significance, School of Veterinary Medicine, University of Tennessee, Knoxville, November, 1975.
  13. Photoaffinity Labeling of the Na++K+-ATPase, Biochemistry Department, University of Kentucky, February 1976.
  14. Drugs, Racehorses and the Kentucky Equine Drug Research Program, National Association of State Racing Commissioners Meeting, San Diego, California, March 1976.
  15. Interaction of Ouabain and Cassaine with Na++K+-ATPase and Its Relationship to their Inotropic Actions, presented at a symposium on Drug Action at the Molecular Level, London, England, April 1976.
  16. The Pharmacology and Pharmacokinetics of Procaine in Thoroughbred Horses, presented at Second Int’l Conference on Research and Doping Control, Newmarket, England, May 1976.
  17. The Pharmacology of Drugs Used in Racing, Seminar, American Association of Equine Practitioners Meeting, Dallas, Texas, November 1976.
  18. Furosemide in the Horse, National Association of State Racing Commissioners, San Juan, Puerto Rico, March 1977.
  19. A Review of the Pharmacology of Furosemide in the Horse, presented to Third Int’l Doping Conference, Rome, Italy, March 1977.
  20. The Pharmacology of Procaine in the Thoroughbred Horse, British Equine Veterinary Association Meeting, Dublin, Ireland, October 1977.
  21. The Pharmacology of Furosemide in the Horse, Cornell University, Ithaca, New York, November 1977.
  22. An In Depth Seminar on Medication and Equine Practice, AAEP Meeting, Vancouver, British Columbia, December 1977.
  23. The Pharmacology of Furosemide in the Horse, Department of Pharmacology, University of Washington, Seattle, December 1977.
  24. Seminars on Procaine and Lasix® in Thoroughbred Horses (Postgraduate Veterinarians Course), Michigan State University, January 1978.
  25. Session Chairman, Pharmacokinetics Section, 1st Conference of American College of Veterinary Pharmacologists, Baton Rouge, Louisiana, March 1978.
  26. "Pre-race Testing", presentation to National Association of State Racing Commissioners, Miami, Florida, March 1978.
  27. Seminar, "The Pharmacology of Furosemide in the Horse," Colorado State University, Fort Collins, April 1978.
  28. Seminar, "The Pharmacology of Furosemide in the Horse," Purdue University, Lafayette, Indiana, April 1978.
  29. Seminar, "Plasma and Urinary Concentrations of Drugs and Pharmacological Effects," Chicago Equine Veterinarians Group, May 1978.
  30. The Pharmacology of Narcotic Analgesics in the Horse: Studies on the Detection, Pharmacokinetics, Urinary Clearance Times and Behavioral Effects of Pentazocine and Fentanyl in the Horse, Fourth Int’l Doping Conference, The Curragh, Ireland, 1978.
  31. White CG, Woods WE, Tobin T: The Pharmacology of Reserpine in the Horse, I. Effects of Reserpine and Imipramine on Platelet Uptake of Serotonin, presentation and publication, Seventh Int’l Congress of Pharm, Paris, France, 1978.
  32. The Pharmacology of Narcotic Analgesics in the Horse, Purdue University, Lafayette, Indiana, November 1978.
  33. Tobin T, Maylin GA, Fregin F et al.: Drugs and Performance Testing in Racehorses, presentation to NASRC, San Francisco, California, March 1978.
  34. Tobin T: Medication Testing in North America, presentation to European analysts, Cologne, Germany, March 1979.
  35. Moderator, Pharmacological Studies on Doping Drugs in Horses, Third Int’l Symposium on Equine Medication Control, Lexington, KY, June 1979.
  36. Tobin T: Lasix® in the Horse, Jockey Club Round Table Conference, Saratoga Springs, New York, August 1979.
  37. Race Horse Medication, Pharmacologic, Forensic and Administrative Considerations, University of Louisville, KY, September 1979.
  38. Overview of Antibiotic Therapy in the Horse, Kentucky Equine Practitioners, November 1979.
  39. Guest Lecturer, College of Veterinary Medicine, University of Missouri, Columbia, Medication and Medication Control in Racing Horses, November 1979.
  40. Equine Pharmacology Workshop, Columbia, Missouri, November 1979.
  41. Overview of Basic Antibiotic Therapy in the Horse, 25th AAEP Meeting, Miami, Florida, December 1979.
  42. Guest Lecturer, Clinical Veterinary Pharmacology, College of Veterinary Medicine, Colorado State University, Fort Collins, January 1980.
  43. The Pharmacology of Furosemide in the Horse, Diagnostic Laboratory, Iowa State University, Ames, February 1980.
  44. Drugs and the Performance Horse, Department Large Animal Medicine, University of Guelph, Guelph, Ontario, March 1980.
  45. Recent Advances in Studies on the Drug-Receptor Complexes, with Special Reference to Na++K+-ATPase and the Opiate Receptor, Second Symposium on Veterinary Clinical Pharmacology and Therapeutics, University of Pennsylvania, June 1980.
  46. Two invited papers on a special session on "Medication in Competing Horses," British Equine Veterinary Association:
  47. (I) Survey of Positive Results from Racecourse Anti-doping Samples in the USA.
  48. (II) Experiences in the Application of Pre-race Dope Testing.
  49. Bayes' Theorem and its Significance in Equine Drug Testing, presented at AORC Conference NASRC Meeting, Lexington, KY, April 1980.
  50. The Pharmacology of Furosemide in the Horse, presented at the 1980 AAEP Meeting, Anaheim, California.
  51. The Pharmacology of the Corticosteroids in the Horse, presented at 1980 AAEP Meeting, Anaheim, California.
  52. The Role of Simple Behavioral Models in Performance Studies. Seminar on Drugs in Horse Racing, Racecourse Security Services, Newmarket, England, February 1981.
  53. Drugs and the Performance Horse, Lexington Rotary Club, March 1981.
  54. Drugs and the Performance Horse, Student Colloquium, Louisiana State University, Baton Rouge, April 1981.
  55. Pharmacology of Acepromazine in the Horse, Fourth Int’l Symposium on Equine Medication Control, Melbourne, Australia, May 1981.
  56. Phenylbutazone Use Under a Controlled Medication Program, Fourth Int’l Symposium on Equine Medication Control, Melbourne, Australia, May 1981.
  57. An Overview of Antibiotics and Anti-Inflammatory Therapy in the Horse, Quebec Veterinarians Conference, Montreal, Canada, September 1981.
  58. An Overview of Performance Horse Medication and Its Control, Mid-American Veterinarians Conference, Louisville, KY, October 1981.
  59. Guest Lecturer, College of Veterinary Medicine, Gainesville, Florida, September/October 1981.
  60. Drugs and the Performance Horse, Student Chapter of AAEP, Gainesville, Florida, October 1981.
  61. "Directions," with Carolyn Kell, thirty-minute television program on Drugs and the Performance Horse, Kentucky Educational Television, October 1981.
  62. Drugs and the Performance Horse, College of Veterinary Medicine, Virginia Tech, Blacksburg, February 1982.
  63. Endotoxin Shock in Horses, American Society for Veterinary Pharmacology and Experimental Therapeutics, Ohio State University, Columbus, April 1982.
  64. Pharmaceutical Manufacturer's Association, invited presentation on "Drugs, Medications, and Racing Horses," Louisville, KY, August 1982.
  65. Symposium on Drugs in Horse Racing and paper on Effects of Drugs on Equine Performance, Fall meeting American Society for Pharmacology and Experimental Therapeutics, University of Louisville, KY, August 1982.
  66. Guest Lecturer, College of Veterinary Medicine, University of Florida, Gainesville, September/October 1982.
  67. QED BBC Television Interview on Anabolic Steroids and Racing Horses, Oxford, England, September 1982.
  68. The Effects of Drugs on Equine Performance, First Int’l Conference on Equine Exercise Physiology, Oxford, England, September 1982.
  69. Drugs, Medications and Breeding Horses, Munster Thoroughbred Breeders Society, Cashel, Ireland, October 1982.
  70. Problems, Perceptions and Scientific Realities in Race Horse Medications, invited presentation, Auburn University, Auburn, Alabama, October 1982.
  71. Drugs and Performance Horses, Kentucky Horsemen's Short Course, October 1982.
  72. Drugs and Performance Horses, University of Calgary, Canada, February 1983.
  73. Drugs and Performance Horses, University of Saskatoon, Saskatchewan, Canada, February 1983.
  74. Drugs and Performance Horses, Harness Horsemen's Association, Columbus, Ohio, March 1983.
  75. Testimony before the Judiciary Committee, Subcommittee on Criminal Justice, Washington, DC, May 1983, "Phenylbutazone, Furosemide and Drug Testing."
  76. Drugs and Racing Horses, College of Veterinary Medicine, University of Illinois, November 1983.
  77. Phenylbutazone and Furosemide in the Racing Horse, Veterinary College of Ireland, Dublin, Ireland, January 1984.
  78. Drugs, Equine Performance, Drugs in the Growing Horse, Horsemen's Short Course, University of Nevada, Reno, February 1984.
  79. Plasma Levels of Phenylbutazone in Racing Horses, invited presentation American Academy of Veterinary Pharmacology and Therapeutics, College Station, Texas, April 1984.
  80. Pain Perception and Control in Equines, Proceedings of the Fifth Int’l Symposium on Equine Medication Control, Toronto, Canada, June 1984.
  81. The Foreign Substance Rule:  Presentation to the Board of the HBPA, Cleveland, Ohio, July 1984.
  82. Drug Detection in Racehorses, Forensic Decisions on Drug Testing in Racehorses, Antibiotics in Equine Medicine, four hours of lecture, South Florida Veterinary Medical Association, Miami, Florida, Labor Day, 1984.
  83. Drugs, Medication Rules and Performance Horses, four hour seminar, The Caribbean Veterinary Medication Association, Trinidad, November 1984.
  84. Medication and Testing for Drugs in Racehorses, Transylvania University, Lexington, KY, February 1985.
  85. Drug Detection in Racehorses, Forensic Decisions Based on Drug Detection in Racehorses and Antibiotics in Equine Medicine, four hour seminar, New Jersey Veterinary Medical Association, Atlantic City, March 1985.
  86. Drug Detection in Racing Horses and Antibiotic Use in Equine Medicine, four hour seminar, Indiana Veterinary Medical Association, Indianapolis, March 1985.
  87. Experiences as an Expert Witness, Educating People While Under Oath, presented at the Sixth Int’l Symposium on Equine Medication Control, Hong Kong, 1985.
  88. Drugs and Racing Horses, New Hampshire Vet Med Assoc., New Hampshire, February 1986, four hours of continuing education.
  89. Keeping Track, California Thoroughbred Breeders Assoc., Breeders Cup Meet, Oct. 27, 1986, Pasadena, California, Use of Medication During a Horse's Racing Career: Does It Mask Inheritable Defects.
  90. Drugs and the Performance Horse, Irish Veterinary Association Meeting, Kildare, Ireland, December 1987.
  91. Immunoassay Testing in Equine Forensic Chemistry, Southern Group, Irish Thoroughbred Breeders, Killoran Lodge, Co. Tipperary, Ireland, September 1988.
  92. ELISA Testing for Drugs:  A New Technology, Institute for Mines and Minerals, Lexington, KY, September 1988.
  93. ELISA Testing for Drugs in Horses:  A New Technology, Bologna, Italy, October 1988.
  94. ELISA Testing for Drugs in Horses:  A New Drug Testing Technology, North American Judges and Stewards Conference, Livonia, Michigan, October 1988.
  95. ELISA Testing for Drugs in Horses, Harness Expo, Pompano Beach, Florida, November 1988.
  96. Performance Effects of Drugs in Horses, American Association of Equine Practitioners, San Diego, California, December 1988.
  97. ELISA Testing for Drugs in Racing Horses, U.N.I.R.E, Rome, Italy, March 1989.
  98. Drugs, Equine Performance and ELISA Testing for Drugs, Equitana, Essen, West Germany, April 1989.
  99. Bain Fallon Lectures, eight lectures on Equine Pharmacology and Drug Testing, Coffs Harbour, Australia, May 1989.
  100. Invited Lecture Tour, North and South Islands, New Zealand, three locations, 18 lectures, May   1989.
  101. Thoroughbred Racing Protective Bureau, ELISA Testing in Racing Horses, Minneapolis, Minnesota, October 1989.
  102. Quality Assurance Program Legal Seminar, St. Louis, Missouri, Trace Levels in Equine Drug Testing, November 1989.
  103. Drug Testing in Racing Horses, four seminars in Mexico City, December, 1989.
  104. Invited presentations, Eighth International Symposium on Equine Medication Control, Harare, Zimbabwe, February 1990.
  105. Southern Arizona Veterinary Medical Association, Tucson, Arizona, six seminars on medication in Racing Horses, June 1990.
  106. ELISA Testing in Racing Horses, Central Kentucky Farm Manager's Club, June 1990.
  107. Five lectures to veterinarians, Buenos Aires, November 1990.
  108. Four lectures to administrators, Buenos Aires, November 1990.
  109. Twelve lectures to Oklahoma Veterinary Medical Association, Oklahoma City, Oklahoma,   January    11-12, 1991.
  110. Drug Testing and the Graduate Center for Toxicology at the University of Kentucky, Kentucky State University, February 1991.
  111. Drug Testing and Exotic Drugs in Racing Horses, Johnson & Wells University, Providence,   Rhode Island, February 1991.
  112. Six presentations to the South African Equine Practitioners Association, February 18-19, 1991, Caledon, Cape Province, South Africa.
  113. Presentation to Cape town Turf Club Members on ELISA Testing and Drug Testing in Racing Horses, February 19, 1991.
  114. Presentation to Durban Turf Club Members on ELISA Testing and Drug Testing in Racing Horses, February 20, 1991.
  115. Presentation to Turffontein (Johannesburg) Turf Club Members on ELISA Testing and Drug Testing in Racing Horses, February 21, 1991.
  116. Expert testimony, South Africa, Affidavit for Turffontein Turf Club on Narcotic Analgesics in Racing Horses.  February 1991.
  117. Four presentations to the Indiana Equine Veterinarians Group on Drugs, Drug Testing and ELISA Testing in Racing Horses, Andersonville, Indiana, March 13, 1991.
  118. Drugs, Racehorses and Illegal Drug Detection, Benedict College, Columbia, South Carolina, April 1991.
  119. Trace Levels of Medications in Racing Horses, invited presentation to the floor, Racing Commissioners International Meeting, Cincinnati, Ohio, May 1991.
  120. American Association of Clinical Chemistry, Southeast Ohio Valley Group, ELISA Based Analytical Procedures: A Revolution in Equine Drug Testing, Lexington, Kentucky, October 12, 1991.
  121. Expert Testimony on Testosterone in Racing Horses on behalf of Iowa Racing Commission Hearing, December, 1991.
  122. Expert testimony, Cook County Courthouse, State vs Wilkie, June, 1991, on behalf of prosecutor.
  123. Two phone depositions, Hearing on Glycopyrollate, California Horse Racing Board, January & February, 1992, commission witness.
  124. Deposition/Affidavit on behalf of the Colorado State Racing Commission on Pharmacology of Isoxsuprine, August, 1992.
  125. Immunology and the Betting Window, presentation to the Clinical Ligand Assay Society, St. Louis, Missouri, November, 1992.
  126. Immunology and the Betting Window.  Presentation to Sigma Diagnostics Group, Sigma Chemical Company, St. Louis, Missouri, November, 1992.
  127. Review of videotape for the Suretie of the Province of Quebec, Quebec, Canada.
  128. Use of Analgesics in Racing Horses and Their Regulatory Control, invited presentation, British Equine Veterinary Association, September, 1993.
  129. Four lectures on Control of Medications in Racing Horses, Royal Western India Turf Club, Bombay, India, January 3, 1994.
  130. Presentation on Control of Therapeutic Medications in Racing Horses, Kunigal Stud, Bangalore, January 5, 1994.
  131. Presentation on Control of Medication in Racing Horses to HRH Prince Miteb, HH Prince Sultan, the Executive Director of the Riyadh Equestrian Club and the club’s veterinarians, Riyadh, Saudi Arabia, January 11, 1994.
  132. Invited presentation on Thresholds and Clearance Times for Therapeutic Agents in Racing Horses, Winter meeting of HBPA, Hot Springs, Arkansas, February 21, 1994.
  133. Invited presentation on Thresholds and Clearance Times for Therapeutic Agents in Racing Horses, ARCI meeting, Los Vegas, Nevada, May 23, 1994.
  134. Invited presentation on No Effect Thresholds for Local Anesthetics in Racing Horses, 10th International Conference of Racing Analysts and Veterinarians, Stockholm, Sweden, July 7, 1994.
  135. Presentation on Workshop on Testing for Therapeutic Medications, Environmental and Dietary Substances in Racing Horses to National Summer HBPA Meeting, Chicago, Illinois, July 25, 1994.
  136. Workshop on Testing for Therapeutic Medications, Environmental and Dietary Substances in Racing Horses, Lexington, Kentucky, August 18-19, 1994.
  137. Invited presentation on the outcome of the Workshop on Testing for Therapeutic Medications, Environmental and Dietary Substances in Racing Horses, AAEP Annual Meeting, Vancouver, British Columbia, Saturday, December 3, 1994.
  138. Invited presentation, panel discussion "Are You Positive You Are Negative", University of Arizona Conference on Racing, Tucson, Arizona, December 8, 1994.
  139. Report on "Thresholds for Therapeutic Medications in Racing Horses", Spring meeting of the National Horsemen's Benevolent and Protective Association, Houston, Texas, April 13, 1995.
  140. The Need for Thresholds for Therapeutic Medications in Racing Horses, Farm Manager's Club, Lexington, Kentucky, April 4, 1995.
  141. Thresholds for Therapeutic Medications in Racing Horses:  A Television/Live Presentation at the ARCI Meeting in Oklahoma City, Oklahoma, April 23, 1995.  Arranged for TV clips by Wayne Lukas, Dick Mandella and John Forsythe, structured program in association with Scott Stanley and Rick Sams.
  142. Television clips:  a) Amantadine and Rimantadine Prophylaxis of Equine Influenza, b) Thresholds for Therapeutic Medications in Racing Horses.  Clips made April 18, 1995, for Derby release.
  143. University of Kentucky Equine Law Seminar, invited presentation on Thresholds in Equine Medication Control, Thursday, May 4, 1995.
  144. Kentucky Equine Research Short Course "Recent Advances in Equine Nutrition", "Drugs and Drug Testing:  What Should the Feed Manufacturer Know," May 11, 1995, Lexington, Kentucky.
  145. Presentation, Irish Turf Club Analytical Laboratory Review Committee, June 21, 1995.
  146. Invited presentation:  "Update on Equine Medication Research," Salishan Lodge, Oregon, July 25, 1995.  Voted Man of the Year by the National HBPA.
  147. Calgary Exhibition and Stampede:  Opinion letter to defuse Chuck Wagon Racing Crisis, August, 1995.
  148. Expert opinion on Clanobutin, The Southern Africa Jockey Club, Nov. 1995.
  149. Invited Review, Irish Turf Club, September 1995, Kildangan Stud, Co Kildare
  150. Invited Presentations on Equine Medication.  Indiana Veterinary Medical Association.  February, 1996.
  151. Invited Presentation, "Doping or Therapeutic Medication" The Dutch Association of Equine  practitioners, Amersfoort, Holland, March 6, 1996.
  152. "Medication and Medication Control in Racing Horses," Hirsch Series Speaker Lectures, the University of Tucson, Tucson, Arizona, March 29, 1996.
  153. Expert opinion on Sodium Bicarbonate:  For the Oregon State Racing Commission, March, 1996.
  154. Invited Presentation, International Conference of Racing Analysts and Veterinarians, Report on Workshop on "Testing for Therapeutic Medications, Environmental and Dietary Substances in Racing Horses, May 1966, Brisbane, Australia.
  155. Invited Presentation, "Therapeutic Medications, “No Effect Thresholds” and the Performance Horse” The Members Room, Kalgoorlie Turf Club, Kalgoorlie, Western Australia, May 27, 1996.
  156. Invited Presentation, “Therapeutic Medications, “No Effect Thresholds” and the Performance Horse” The Southern Districts Thoroughbred Association Supported by The Breeders, Owners, Trainers, and Reinsmen Association Trotting Association, Golden Nugget Room, Gloucester Park, Perth, Western Australia, May 30, 1996.
  157. Invited Presentation, “Therapeutic Medications, “No Effect Thresholds” and the Performance Horse” A Presentation at Ellerslie Racecourse, Auckland, New Zealand, June 1, 1996.
  158. “Therapeutic Medications, “No Effect Thresholds” and the Performance Horse” A Presentation to Equine Practitioners and Regulators, Auckland University Medical Center, New Zealand, June 2, 1996.
  159. “The Detection, Actions, Uses and Effects of Drugs and Medications in Performance Horses”.  A series of seminars to BHP staff, Limerick, Ireland, July 1-5, 1996.
  160. “The Philosophical Basis For “No Effect Thresholds” or “NETs.”  Annual Conference of the American Veterinary Medical Association, Louisville, Kentucky July 21, 1996.
  161. South American Anti-Doping Technology and Medication Testing Conference - The Jockey Club of Brasiliero.  August 8th and 9th, 1996, The Rio De Janeiro JCB Central Offices.
  162. “Performance Affection Agents and Medications in Racing Horse:  An Overview of Their Uses and Effects in Racing Horses”
  163. “Testing for Performance Affecting Agents and Medications in Racing Horses”
  164. “Testing for Therapeutic Medications, Environmental and Dietary Substances: The Need for Limited Sensitivity Testing”.
  165. “The North American Approach to Medication Control; The ARCI Foreign Substances Classification System and the American Association of Equine Practitioners Therapeutic Medication List”.
  166. “No Effect Thresholds”:  One North American Approach to Limiting the Sensitivity of Testing for Approved Therapeutic Agents.
  167. The Jockey Club of Sao Paulo, Sao Paulo, Brazil, August 12th, 1996.  Two hour seminar on “Equine Medication Control in North America and “No Effect Thresholds” or NETS.
  168. UNESP at Jaboticabal, Jaboticabal Veterinary School, August 13th, 1996. One hour seminar on “Equine Medication Control in North America and “No Effect Thresholds” or NETS.
  169. Presentations to the “Confederacion Hipica De Puerto Rico, Inc.” Second Technical Convention. El Conquistador Beach Resort, Puerto Rico, Sept. 15th, 1996.
  170. Trinidad and Tobago Racing Authority, Santa Rosa Racing Facility, Churchill Roosevelt Highway, O’Meara, Arima, Trinidad.  September 27th, 1996.
  171. “Performance Affecting Agents and Medications in Racing Horse:  An Overview of Their       Detection, Actions, Effects and Uses.”
  172. “Limited Sensitivity Testing for Therapeutic Medications, the ARCI Foreign Substances Classification System, the American Association of Equine Practitioners Therapeutic Medication List and Developing “No Effect Thresholds” or NETs.
  173. Environmental and Dietary Contaminants and “Positives”. AAEP Denver, Sunday, December 8, 1996.
  174. Quantification of Pharmacological Response in the Horse.” U of Arizona RTIP, Tucson, Dec 11th, 1996.
  175. "Thresholds Research Progress.”  Two presentations to HBPA December 15th and 16th, Phoenix, AZ, Dec. 1996.
  176. Video Teleconference; “Overview of Medication Control” distance seminar format for Maryland practitioners, presented, March 1997.
  177. Presentations on “Drug Detection and Control in Racing Animals” at the Scientific Centre for Racing Camels, Al Ain, Abu Dhabi, United Arab Emirates, April 7-8th 1997.
  178. “Regulators, Regulations and the Marketing of Therapeutic Medications” April 16-17th 1997, Merck Inc., Rahaway, New Jersey.
  179. Presentation on Equine Protozoal Myelitis, Equine Dressage Clinic, New Jersey. April 19th 1997.
  180. Presentation on analytical/pharmacological relationships for Lidocaine, Association of Racing Commissioners International meeting.  Boston, Sunday April 20th, 1997.
  181. Review of analytical/pharmacological relationships for therapeutic and performance altering drugs, seminar presentation, BHP, Limerick, Ireland, July 3, 1997.
  182. Presentation on “Developing and Marketing ELISA Tests in an Evolving Regulatory Environment”.  Washington, DC. July 17-18th, 1997.
  183. “Analytical/Pharmacological Relationships for Therapeutic Medications”.  Summer HBPA conference, Las Vegas, Nevada, 1997.
  184. “Analytical Pharmacological Relationships: An Overview of Progress”.  Testing Integrity Program, New Bolton Center, Philadelphia, PA., September, 1998.
  185. Presentation on “Lasix and EIPH” on behalf of the Thoroughbred Owners & Breeders Association.  The Breeder’s Cup, Hollywood Park, California, 1997.
  186. “Analytical Pharmacological Relationships” update on progress in this field.  Presented to the National HBPA, Ft. Lauderdale, Florida, January, 1998.
  187. Television clip – Superscience “Diclazuril and EPM,” Monday, February 9th, Channel 36.
  188. Presentation on “Diclazuril and Equine Protozoal Myelitis” Eighth International Conference on Infectious Diseases.  Dubai, United Arab Emirates, March 1998.
  189. Presentations on “Analytical-Pharmacological Relationships,” Reviews and specific cases, the 12th International Conference of Racing Analysts and Veterinarians, Vancouver, British Colombia, April, 1998.
  190. “Hay, Oats & Water – Then (?) and Now,” Presentation to the Thoroughbred Owners of California, July 23, Del Mar, California, 1998.
  191. “Hay, Oats & Water – Then (?) and Now” Presentation to the Medication Committee and the Board of the National HBPA, Des Moines, Iowa, July 26th and 27th, 1998.
  192. “EPM and the Performance Horse: New Treatments and Management Options” Presented at the Kentucky Horse Council Seminar, Red Mile Place, Lexington, November 25th, 1998.
  193. “Limits on the Sensitivity of Testing” Conference on Applied Biotechniques in the Equine, Brazilian Horse Breeders. Belo Horizonte, Brazil, November 25th, 1998.
  194. “Limits on the Sensitivity of Testing” Sao Paulo Veterinarians and Regulators Group, Sao Paulo, Brazil, November 26th, 1998.
  195. “Limits on the Sensitivity of Testing” College of Veterinary Medicine, Jaboticabal, Brazil, November 27th, 1998.
  196. Representing Testing Integrity Program (TIP) at the Racetrack Industry Testing Program, Tucson, Arizona, December 10th, 1998.
  197. “Analytical Techniques in Racing Chemistry” BHP Laboratories, Limerick, Ireland. January 8th, 1999.
  198. “Limitations of the Sensitivity of Testing”. Presentation to Harness Racing Stewards, Perth, WA, January 11th, 1999.
  199. Clenbuterol:  Review of current research in this area.  Presentation to the Medication Committee, National Horsemen’s Benevolent & Protective Association, January 16th, Ft. Lauderdale, FL.
  200. Seminar for Merial on introduction of Omeprazole in Equine Market.  Boston, MA, February       26,1999.
  201.  “Panel of Experts on Medication” March 6th, 1999, Orlando Florida. Thomas Tobin, Richard Sams, George Maylin, and Thomas Lomangino. Hosted by Stan Bergstein of Harness Tracks of America.
  202. Six plus presentations to the Association of Official Racing Chemists on Drug Testing in Racing Horses, March 10th - March 16th, 1999, New Orleans, Louisiana
  203. Presentation on Drug Testing and medication control, March 26th, 1999, Dover, Delaware, Seminar @ Delaware Harness Commission Offices.
  204. Seminar on Medication Control, June 24,  25th, 26th, 1999, Boston, MA for The Controlled Release Society.
  205. Attendance at the National Council of Legislators from Gaming States (NCLGS) Seminar, July 11th, 1999, Louisville, KY
  206. Presentation on Clenbuterol, July 16th - 17th, 1999, Chicago, Illinois.  Association of Racing Commissioners International (ARCI) Workshop.
  207. Attendance at Summer Meeting of The Horsemen’s Benevolent and Protective Association Meeting, August 2nd - 6th, 1999, Seattle, Washington.
  208. Presentation to Thoroughbred Owners of California, Del Mar Racetrack, August 7th, 1999, San Diego, California.
  209. “Seminar on Clenbuterol”; August 21st, 1999; Association of Racing Commissioners International, Del Mar Hilton; San Diego, CA
  210. Presentation on Clenbuterol Regulation. October 9th - 11th, 1999, Palm Beach, FL.  Presentation on Clenbuterol Regulation.  National Association of Pari-mutuel Regulators.
  211. Presentation on “Equine Medication Control: Clenbuterol and Cocaine.”  National HBPA Meeting, New Orleans, LA, January 30 - February 1, 2000.
  212. “SuperTesting”:  Seminar at the Gluck Equine Research Center with Mr. James Gallagher of the NTRA February 7th, 2000.
  213. Organization of Racing Investigators, Keeneland, Lexington, KY.  “Past, Present and Future of Horse Drug Testing”.  Wednesday, March 22nd, 2000.
  214. Testing Integrity Program, Davis, California.  March 30th - April 1, 2000.  Presentations on Clenbuterol, Cocaine and Pyrilamine.
  215. “Therapeutic Medication of Racing Horses: A Short Course”; Kentucky Racing Commission/Kentucky Racing Commission/Kentucky Equine Drug Council.  Short Course, Three Hours.  Keeneland, April 21st, 2000.
  216. New Directions in Equine Drug and Medication Testing.  Equine Law Section of the Kentucky Bar Association.  Marriott Griffin Gate, May 3, 2000.
  217. “Therapeutic Medication of Racing Horses:  A Short Course”:  Kentucky Racing Commission/Kentucky Racing Commission/Kentucky Equine Drug Council.  Short Course, Three Hours.  Churchill Downs, June 8, 2000.
  218. Invited presentation and discussion group on Product Entry into the Equine Market, Boehringer/3M at the 3M Corporate Retreat, Wonewok, Wisconsin, Juhe 9-12, 2000.
  219. Representing the Department and the College of Agriculture at the “Memoire” of Mr. Cedric Holtz, Dijon, France, July 26, 2000.
  220. Review of Equine Research.  National Horsemen’s Benevolent and Protective Association, Minneapolis, Minnesota, August 4, 2000.  Charles Hughes and Thomas Tobin
  221. Clenbuterol in the Horse: An Overview.  The 3M Corporation, Minneapolis, Minnesota, August 5, 2000.  Charles Hughes and Thomas Tobin.
  222. Invited presentation to 13th International Conference of Racing Analysts and Veterinarians.  “No Effect Levels – an Overview and a Pharmacological Approach.”  Cambridge, England, August 9, 2000.
  223. “Therapeutic Medication of Racing Horses:  A Short Course”:  Kentucky Racing Commission/Kentucky Racing Commission/Kentucky Equine Drug Council.  Short Course, Three Hours.  Ellis Park, June 8, 2000.
  224. Eighth Testing Integrity Workshop.  “High Sensitivity and High Throughput ELISA and Mass Spectral Analysis.”  Lexington, Kentucky.  October 6,7, and 8, 2000.
  225. “Therapeutic Medication and Racing Horses: A Short Course.”  Extended program with three guests faculty and 50+ registrants.  Churchill Downs, Louisville, KY.  October 31, 2000.
  226. “Medication: Then and Now.” Stewards Accreditation Short Course. University of Louisville, November 13, 2000.
  227. Invited panelist, “Therapeutic Medication and the Racing Horse.”  The American Association of Equine Practitioners Meeting, San Antonio, Texas. November, 2000.
  228. Invited speaker, Testing Integrity Program, Race Track Industry Program. Tucson, Arizona.  December, 2000.
  229. Therapeutic Medication & Racing Horses: A Short Course: Turfway Park, LLC, Florence, Kentucky. March 20, 2001.  Guest Faculty: Dr. Mitzi Fisher, Dr. Thomas Wood; 40 registrants.
  230. Therapeutic Medication & Racing Horses: A Short Course: Turfway Park, LLC, Florence, Kentucky. March 20, 2001. Guest Faculty: Dr. Mitzi Fisher, Dr. Thomas Wood; 40 registrants.
  231. The Commission Veterinarian/Equine Medical Director 2001: A Short Course: Kentucky Derby Museum, Louisville, Kentucky.  May 1-2, 2001.  Extensive guest faculty; 80+registrants/participants, extensive international list of attendees.
  232. Presentation on the Mare Reproductive Loss Syndrome (MRLS), Keeneland, May 28th, 2001.
  233. Board Meeting, Thoroughbred Owners of California, Del Mar, California, Saturday, July 21st, 2001.
  234. With Dr. Levent Dirikolu, presentation on Formulation Strategies for Clazuril Anti-Protozoals, Bayer Animal Health, Kansas City, Kansas, August 10th, 2001.
  235. “Zero Tolerance – A Myth” presentation to the Board of the National Horsemen’s Benevolent and Protective Association, Copley Plaza, Boston, MA, Monday, August 13th, 2001.
  236. College of Veterinary Medicine, Cordoba, Argentina, August 16th, 17th and 18th – 14 lectures in Continuing Education Short Course, Honorary Faculty Member, College of Veterinary Medicine of the Province of Cordoba.
  237. Cordoba:  History of Equine Medication Control:  Medication Control from the early Eighteen-hundreds to today.
  238. Cordoba:  Equine Drugs and Medications:  Their absorption, distribution, metabolism and elimination in the horse.  Equine Drug Metabolism:  an overview of why chemists test horse urine.  Equine Drug Testing: an overview.
  239. Cordoba:  An overview of the Pharmacological Actions of Performance altering Drugs effects, including how drugs and medications are used to influence racing performance.
  240. Cordoba:  The “NO Effect Threshold” concept and how “No effect Thresholds” are developed.
  241. Cordoba:  The Narcotic Analgesics and their actions and detection in the Horse.
  242. Cordoba:  Central Stimulant Drugs and their actions and effects.
  243. Cordoba:  Selected Tranquilizers and their actions and effects (class 2 agents).
  244. Cordoba:  Selected Tranquilizers and their actions and effects (class 3 agents).
  245. Cordoba:  Selected Bronchodilators and their actions and effects.
  246. Cordoba:  Selected Non-steroidal Anti-inflammatory Medications and their actions and effects.
  247. Cordoba:  Furosemide and other agents used in the control of Exercise Induced Pulmonary Hemorrhage….
  248. Cordoba:  Anabolics and their actions and effects.
  249. Cordoba:  The rules of the Therapeutic Road.
  250. Cordoba:  Equine Protozoal Myelitis:  A New Therapeutic Approach.
  251. Dubai Grass Sickness Research Group, Dubai, UAR. Presentation on “Toxicokinetics of Cyanide in the Horse”, September 22nd, 2001. Dubai Millennium Medal.
  252. Chicago Hilton, Boehringer Ingelheim Working Group on Torpex. Presentation on Detection Times for Albuterol after Administration by Torpex. October 16th, 2001.
  253. Keeneland Racecourse. Presentation and Press Conference on “Proposed Policy on Drug and Medication Testing” by the National Horsemen’s Benevolent and Protective Association., October 18th, 2001.
  254. Attendance and Presentations at TIP Meeting and AAEP Medication Summit, Tucson, Arizona, December 2001.
  255. “Overview of the Proposed Policy on Drug Testing and Medication Control,” Las Vegas, Nevada, Tuesday, January 22nd , 2002.
  256. “An Overview of MRLS”, Karakata Sales Complex, Karakata, New Zealand. Sponsored by the University of Auckland, January 26th, 2002.
  257. “An Overview of Equine Medication Research”.  Presented to the Board of the Florida                    HBPA, Gulfstream Park, February 14th , 2002.
  258. Equine Medication Control Thresholds: An Overview. The Conference Center, Bank of Nova Scotia, Kingston, Jamaica, April 18th, 2002.
  259. Furosemide and EIPH: An Overview. The Conference Center, Bank of Nova Scotia, Kingston, Jamaica, April 18th, 2002.
  260. Highest No-Effect Dose for Pharmacological Responses to Acepromazine in the Horse: A Preliminary Communication.  Presented to the Research Committee of the Testing Integrity Program, May 1st, 2002.
  261. “ELISA Testing of Racing Horses: A Regulatory Revolution”.  Presented for the California Association of Toxicologists, Tempe, Arizona, May 18th, 2002.
  262. “Town and Gown: Academic ‘Spin-offs’ in the Bluegrass”.  Presented to the Lexington Kiwanis Club, Kentucky Inn, Lexington, Kentucky, July 9th, 2002.
  263. Intellectual Property Presentation with Videotape in Support of a Patent Application on a New Equine Sedative, Analgesic and Tranquilizer.  The Patent Office, Washington, D.C., July 11th, 2002.
  264. Presentation to Medication Committee of the National Horsemen’s Benevolent and Protective Association, Vancouver, Canada, July 19th, 2002.
  265. An overview of current drug issues in racing and comparison of medication rules around the world. Australian Equine Veterinary Association invited lecture, Bain-Fallon Lectures, The Gold Coast, Australia, July 2002.
  266. Practical experiences with drug testing in the pre-purchase in the USA and other places. Australian Equine Veterinary Association invited lecture, Bain-Fallon Lectures, The Gold Coast, Australia, July 2002.
  267. Factors affecting the excretion time and detection limits for NSAIDs-PBZ, Finadyne, ketoprofen, Meclofenamic acid, meloxicam, etc. Australian Equine Veterinary Association invited lecture, Bain-Fallon Lectures, The Gold Coast, Australia, July 2002.
  268. Sensitivity of testing, threshold levels and minimum pharmacologic activity. Australian Equine Veterinary Association invited lecture, Bain-Fallon Lectures, The Gold Coast, Australia, July 2002.
  269. Excretion and detection of corticosteroids – triamcinolone, DepoMedrol, Voren depot, dexamethasone, betamethasone, etc. Australian Equine Veterinary Association invited lecture, Bain-Fallon Lectures, The Gold Coast, Australia, July 2002.
  270. Anabolic steroids – excretion and detection of oil and water based, injectable and oral. Australian Equine Veterinary Association invited lecture, Bain-Fallon Lectures, The Gold Coast, Australia, July 2002.
  271. Sedatives – excretion and detection. Australian Equine Veterinary Association invited lecture, Bain-Fallon Lectures, The Gold Coast, Australia, July 2002.
  272. Excretion and detection of medications used to treat respiratory tract disease e.g. clenbuterol, dembrexine, Lasix, etc., nebulized drugs vs systemic. Australian Equine Veterinary Association invited lecture, Bain-Fallon Lectures, The Gold Coast, Australia, July 2002.
  273. Look to the future new drugs, new tests and an overview of MRLS research. Australian Equine Veterinary Association invited lecture, Bain-Fallon Lectures, The Gold Coast, Australia, July 2002.
  274. Drug and Medication Testing and Its Regulatory Control. Stewards Short Course, Retama Park, San Antonio, Texas, September 17, 2002.
  275. Erythrophleum in Racing Horses: Detection and Regulatory Control. Stewards Short Course, Retama Park, San Antonio, Texas, September 17, 2002.
  276. Shock Wave Therapy in Racing Horses: Detection and Regulatory Control. Stewards Short Course, Retama Park, San Antonio, Texas, September 17, 2002.
  277. Presentation on new Kentucky Medication Rule. Kentucky Racing Commission Meeting, The Red Mile, September 24, 2002.
  278. “Drug and Medication Detection in Racing Horses.” Kentucky Equine Management Internships, Gluck Equine Research Center, Lexington, Kentucky, October 9, 2002.
  279. Drug and Medication Testing and Regulatory Control in Racing Horses. Stewards Short Course, Louisville, Kentucky, November 12, 2002.
  280. Town and Gown: Academic “Spin-offs” in the Bluegrass, with a minor in caterpillars. Presented to the Lexington Sunrise Rotary Club, The Lafayette Club, Lexington, Kentucky, November 26, 2002.
  281. Phoenix Arizona, National Horsemen’s Benevolent and Protective Association, Winter Meeting. Presentation on National HBPA Proposed Policy on Drug Testing and Therapeutic Medication. January 26, 2003.
  282. New Orleans, Louisiana. National Horsemen’s Benevolent and Protective Association Winter Convention. January 31, 2004.
  283. Atlanta, Georgia. Clayton State University Biology Seminar. March 9, 2004.
  284. Dubai, UAE: 15th International Conference of Racing Analysts and Veterinarians, March 19-26, 2004.
  285. Portland Oregon: National Horsemen’s Benevolent and Protective Association Summer Meeting, July 21st-24th, 2004
  286. Louisville KY. American Association of Equine Practitioners workshop, Brown Hotel, Louisville, July 25th, 2004.
  287. Istanbul Turkey, Invited Presentation, International Racehorse Owners Association, August 21st- 24th, 2004.
  288.  Rio Jockey Club, Nov 1st, 2004
  289. Congreso Mundial Equino Confepaso, November 19-21, 2004.
  290. January 15-18 2005 ,  National Horsemen’s Benevolent and Protective Association Winter Meeting, San Antonio, Texas, Presentation on the matter of trace level morphine identifications and regulatory approaches to the same
  291.  Attended Equine Guelph Research Meeting as representative of Ontario Horsemen’s Benevolent and Protective Association and  as Equine Guelph Grant Reviewer.  Feb 15th-16th, 2005 
  292.  Visit to Oklahoma City to present to the Oklahoma Horse Racing Commission concerning medication rules. June 16th, 2005
  293.  November 21–23, 2005, Congreso Mundial Equino Confepaso, Fedequinas Congress San Juan, Puerto Rico, Review of Equine Drug Testing, Performance Affecting Substances and Regulation of Therapeutic Medications in Paso Fino Horses
  294.  National Horsemen’s Benevolent and Protective Association, Summer Meeting, Toronto, Ontario, Canada, July20-24th 2005. Presentation on the matter of trace level identifications of dexamethasone in racing horses
  295.  Proc 51st Annual Convention American Association of Equine Practitioners Seattle, Washington, Dec3-6th, 2005.  Camargo FC, Tobin T: “A Review   of Environmental Morphine Identifications (EMIs): Worldwide Occurrences and Responses of Authorities”. Proc 51st Annual Convention American Association of Equine Practitioners pp 58-64, 2005.
  296. Presentation at 52nd Annual Convention American Association of Equine Practitioners, December 2006, San Antonio, Texas; presentation, Camargo FC, Hughes C, Lehner AF, Stirling K, Tobin T: “Trace” Benzoylecgonine (BZE) Identifications In Post-Race Urines: Probable Sources And Regulatory Significance Of Such Identifications. In Press, Proc 52nd Annual Convention American Association of Equine Practitioners, December 2006, San Antonio, Texas
  297.  Congreso Mundial Equino Confepaso, Fedequinas Congress, Bogota, Colombia, October  2006 .28th and 29th,two platform presentations, “Avoiding Inconsequential "Positives": The Rules of the Regulatory Road for Regulators” T. Tobin and K.H. Stirling and “Horsemen Avoiding Positives: The Rules of the Therapeutic Road” T. Tobin and K.H. Stirling.
  298. 16th International Conference of Racing Analysts and Veterinarians, Tokyo, Japan, October 21-27th, 2006, platform presentation “Synthesis of deuterated analytical standards:  Ketoprofen-d3 and Flunixin-d3. Proceedings of the 16th International Conference of Racing Analysts and Veterinarians, Tokyo, Japan.
  299. August 15th 2006, Thoroughbred Owners of California (TOC), Annual Medication Meeting, invited presentation, donation in support of Gluck research program, presentation on deriving thresholds for therapeutic medications and visit with UC Davis faculty and CHRB and TOC staff.
  300.  National Horsemen’s Benevolent and Protective Association, Summer Meeting, Minneapolis, July 13th-14th 2006, Invited presentation on the “Brass Hat” matter and the need for concentrations thresholds for therapeutic medications
  301. American Endurance Riders Annual Conference (AERC), San Antonio Texas, February  24-25, 2006. Crowne Plaza Riverwalk, San Antonio “Thomas Tobin, University of Kentucky’s Gluck Equine Research C
  302. Visit to Abu Dhabi, personal guest of HH Sheik Sultan, of the Abu Dhabi Royal Family; January 16-19th 2006. Review of Endurance Racing and discussions and presentations concerning same and invitation to support UK research Program
  303. National Horsemen’s Benevolent and Protective Association Winter Meeting, Tampa Florida, January, 13th-14th 2006. Presentation on the matter of trace level benzoylecgonine detections, with particular reference to recent matters in Indiana and West Virginia.
  304.  Orlando Florida, December 1-4, 2007. Attendance at Orlando AAEP meeting and   presentation of paper on regulatory thresholds for caffeine and related substances.
  305.  Buenos Aires, Montevideo, Sao Paulo, November 2-13th 2007. Presentations in  Buenos Aires, lecture series the Uruguayan Veterinary Medical Association November 8-9th, 10 lectures covering various aspects of equine drug testing and therapeutic medication
  306. Sao Paulo, Nov 10-12th 2007. Guest of Sao Paulo, Jockey Club, review of Sao Paulo,  equine drug testing laboratory, race named in honor of and visit with Senior Sao Paulo Jockey Club Member Baroness Margarida Polak Lara
  307. Tokyo Japan 16th October 21-26TH 2007. Attended the International Conference of Racing Analysts and Veterinarians, and gave a platform presentation on Certified Reference Standards
  308. Bogotá Colombia, October 28-29th 2007. Attended Fedequinas Association Biannual International Congress and gave two Invited platform presentations on therapeutic medication regulation
  309. Williamsburg, Virginia July 17-20 2007. Attended the summer National Horsemen's   Benevolent and Protective Association meeting and gave a platform presentation to the meeting
  310.  San Diego, California, December 4-6, 2008.   Attendance at AAEP at San Diego and presentation of paper on regulatory thresholds for therapeutic medications
  311.  Antalya, Turkey, October 11- 17, 2008. Attended 17th international conference of Racing Analysts and Veterinarians, one platform presentation on tramadol in horses, and three  Coauthored presentations
  312. Toronto Ontario, September 23-24, 2008. Presentation to Ontario to racing commission group on thresholds for morphine in post-race samples, supported by the Ontario HBPA.
  313. West Chester, Pennsylvania, August 4-5, 2008. Visit with Pennsylvania Equine Drug Testing and Research laboratory and the University of Pennsylvania at Kennett Square as part of a certified reference standards Project
  314. Hershey, Pennsylvania, July 18-20, 2008. Attendance at summer meeting of the  National Horsemen's Benevolent and Protective Association, presentation on the 2008 iteration of the National HBPA Proposed Policy for Drug Testing and Therapeutic Medication Regulation
  315. Davis, California, April 27-30, 2008. Attendance at Racing & Medication Testing Consortium workshop on Anabolic Steroid Analysis, on behalf of the National Horsemen's Benevolent and Protective Association
  316. Lexington, Kentucky, April 17, 2008. Attendance at Fourth Kentucky Innovation and Enterprise Conference and poster presentation 
  317. New Orleans, Louisiana, January 24-27, 2009. Attendance and presentation on anabolic steroid testing at the National Horsemen's Benevolent and Protective Association Winter Conference .
  318. Shepherdstown, WVA . (2009) Oral presentation at National Horsemen's Benevolent and Protective Association Summer Convention , Thresholds: How we got to where we are, the Indiana project, and where we are heading
  319. Dublin, Ireland November 7th (2009) Oral presentation at University College.  Equine Medication Regulation: 1800 to November 7th, 2009.
  320. Dublin, Ireland (2009) Oral presentation at Irish Veterinary Association Equine Division.  The Mare Reproductive Loss Syndrome in Kentucky, 2001/2002
  321. Tucson, AZ  (2009) Oral presentation at National Horsemen's Benevolent and Protective Association Winter Meeting,  Anabolic Steroid Regulation: An "OK" Proposal
  322. Queenstown, New Zealand , March 7-13 (2010) Oral presentation at 18th International Conference of Racing Analysts and Veterinarians “Certified Reference Standards and Stable Isotope Internal Standards for Equine Therapeutic Medication Regulation”
  323. Queens Town, New Zealand, March 7-13 (2010) Oral presentation at 18th International Conference of Racing Analysts and Veterinarians “The role of expert testimony in adversarial proceedings.”
  324. Queens Town, New Zealand , March 7-13 (2010) Oral presentation at 18th International Conference of Racing Analysts and Veterinarians “Experiences as an Expert: Educating People While Under Oath, 25 Years since Hong Kong”
  325. Minneapolis, Minnesota  July 23rd (2010)  Presentation at National HBPA Summer meeting “Fatal Musculoskeletal Injury Rates, Thresholds For Phenylbutazone And Pre-Race  Examinations: A Preliminary Report”
  326. Hot Springs, Arkansas, March 17th, 2011.  The McKinsey Report: 20 Years Later. Presentation to the National Horsemen's Benevolent and Protective Association Winter Meeting.
  327. Seattle Washington. Thomas Tobin, To Race or not to Race on Lasix: The Ethical Dilemma: Presentation to the National Horsemen's Benevolent and Protective Association Summer Meeting, Seattle, Washington, Friday, July 22st, 20211.
  328. Racing Medication and Testing Consortium/ Association of Racing Commissioners International Medication Advisory Committee Meeting, Baltimore, Maryland, January 9th, 2012.
  329. Fort Lauderdale, Florida, Lasix Revisited: The American Horsemen’s Story: National Horsemen's Benevolent and Protective Association Winter  Meeting Saturday, January 14, 2012.
  330. Summer meeting, June 28th , National Horsemen’s Benevolent and Protective    Association [NHBPA], Des Moines, Iowa.
  331. 1/ Presentation “Furosemide: lack of effect on numbers of racing starts.”  Kimberly Brewer and Thomas Tobin.
  332. Buenos Aires Presentations for the Organización Sudamericana de Fomento del Sangre Pura de Carrera  Buenos Aires  at San Isidro Racetrack, Buenos Aires, Argentina
  333. Buenos Aires Monday July 2nd,  
  334. ,1.1/ “Trace level identifications of human therapeutic substances transferring from human to horses; an overview of the current situation”  Thomas Tobin and Kimberly Brewer
  335. 1.2/Screening methods/ELISA Tests: Thomas Tobin and Kimberly Brewer
  336. Buenos Aires 1.3/ Thresholds for therapeutic medications: Thomas Tobin and Kimberly Brewer  
  337. Buenos Aires 1.4/ Environmental substances/pollution: Thomas Tobin and Kimberly Brewer
  338. Buenos Aires 1.5/ Factors which affect withdrawal times of therapeutic drugs used in sports horses: Thomas Tobin and Kimberly Brewer
  339. Buenos Aires Tuesday,  July3nd, 2012 Buenos Aires Thomas Tobin and Kimberly Brewer
  340. Buenos Aires 2.1/ Troublesome drugs + those which most usually give positive results.  which are they, and why do they test positive? Thomas Tobin and Kimberly Brewer
  341. Buenos Aires 2.2: Avoiding unnecessary positive results. Thomas Tobin and Kimberly Brewer
  342. Buenos Aires 2.3: Clarifying definitions, so that veterinarians who work either at private practice or doping control laboratories may share the same meanings when it comes to specific language. Thomas Tobin and Kimberly Brewer  
  343. Buenos Aires 2.4: / Animal welfare + increase of its importance at a world-wide basis   + relationship with thoroughbreds: Thomas Tobin and Kimberly Brewer
  344. Soring KH, Brewer K, Kind AJ and Tobin (2012) FOREIGN SUBSTANCES REPORTED IN IOWA RACING, 2001 – 2011:  A REVIEW AND ANALYSIS, Presented at the 19th International Conference of Racing Analysts and Veterinarians, Philadelphia Pennsylvania, September 15-22, 2012. [UK #400, Ag. Experiment Station Number, 12-14-098]
  345. Kind AJ, Soring K, JD, Brewer K , Eisenberg, R.,  Hughes CG, Hartmann-Fishbach, P  and Tobin T (2012) Cathinone and Related “Bath Salt” Substances – Detection in Equine Urine and Potential Sources, Presented at the 19th International Conference of Racing Analysts and Veterinarians, University of Pennsylvania, Philadelphia, Pennsylvania, September 2012. [UK401, Ag. Experiment Station Number, 12-14-099]
  346. Gutierrez J, Eisenberg R, Ferguson EM, Hughes C and Tobin T (2012) “Synthesis of myo-inositol trispyrophosphate (ITPP)  for use as an analytical standard” Presented at the 19th International Conference of Racing Analysts and Veterinarians, Philadelphia, Pennsylvania, September 15-22, 2012. [UK 398 Ag. Experiment Station Number, 12-14-100] .
  347. Kudrimoti S, Gutierrez J, Eisenberg R, Ferguson EM, Hughes C and Tobin T (2012) Synthesis of 3-Hydroxy-mepivacaine-d3 as an Internal Standard for Equine Medication Regulation  Presented at the 19th International Conference of Racing Analysts and Veterinarians, University of Pennsylvania, Philadelphia, Pennsylvania, September 2012. p128-135. [UK 402 Ag. Experiment Station Number, 12-14-101]
  348. Chairperson, Session on the “Detection of New Drugs” 19th International Conference of Racing Analysts and Veterinarians, University of Pennsylvania, Philadelphia, Pennsylvania, September 2012
  349. Scientific Conference, Pittsburgh, Pennsylvania, Friday, September 28th  2012 with Dubai Veterinarians representing Sheik Mohammed bin Rashid al Maktoum.    
  350.  Baltimore Racing Medication and Testing Consortium Scientific Advisory Committee Meeting,  Baltimore, Maryland, Monday, October 22 and Tuesday October 23rd, Saturday, February 23, 2013
  351. Scientific Conference, Dubai UAE, February 14th, 2013 with Dubai Veterinarians representing Sheik Mohammed bin Rashid al Maktoum.    
  352. Scientific Conference, Dubai UAE, Wednesday, July 3rd to Monday, July 8th and three visits to the Dubai MER Laboratory.
  353. National HBPA Summer Meeting, Mystic Lake Casino, Shakopee, Wisconsin,  presentation entitled Clenbuterol: Unusual Aspects of its Urinary Detection/Excretion. 
  354. Denver, Colorado, September 17th, attendance and brief presentation to the Racing Medication and Testing Consortium,[RMTC],  Denver,  Colorado, meeting attended on behalf of the National HBPA.
  355. December 1-15th 2013: Travel to Dubai, United Arab Emirates and presentation to Dubai authorities on aspects of Equine physiological optimization and medication regulation.
  356. National HBPA Winter Meeting, Pasadena, California,  Saturday January 25th,  Thomas Tobin, Kimberly Brewer and Charlie Hughes “Scientifically validated regulatory thresholds for use in racing regulation” Presentations and associated panel discussion.
  357. Kentucky Association of Equine Practitioners meeting January 28th, 2014 “Scientifically defined thresholds/ withdrawal time guidelines for racing regulation”  by Thomas Tobin, Kimberly Brewer and Charlie G. Hughes  Red Mile, Lexington, KY, 40511, Presentations and associated panel discussion.
  358. Darley Flying Start Student Seminar: “Furosemide and EIPH: Efficacy and Controversy: The American Horsemen’s Story”: Friday, January 31st, 2014, at the Maxwell H. Gluck Equine Research Center
  359. Third Annual Univ. of Kentucky Equine Showcase, February 5th, Thomas Tobin, Kimberly Brewer and Charlie Hughes “Where did that positive come from? Let me count the ways”  Four Points Sheraton, 1938 Stanton Way, Lexington, KY 40511. Presentations and associated panel discussion
  360. 5) Racing Medication and Testing Consortium Board Meeting, Gulfstream Park, Florida, March 17th, 2014, attendance as alternate National Horsemen’s Benevolent and Protective Association and brief presentation to the Racing Medication and Testing Consortium Board meeting attended on behalf of the National HBPA.. 
  361.  National HBPA Summer Meeting, Oklahoma City, Saturday, August 16th 2014 , Thomas Tobin, Kimberly Brewer and Charlie Hughes “Cobalt, Lasix, Thresholds and Withdrawal Times; An Overview”  Presentation to Summer Meeting audience as part of a panel discussion on Cobalt and Lasix and associated panel discussion.
  362. 5) Racing Medication and Testing Consortium Board Meeting, Gulfstream Park, Florida, March 17th, 2014, attendance as alternate National Horsemen’s Benevolent and Protective Association and brief presentation to the Racing Medication and Testing Consortium Board meeting attended on behalf of the National HBPA.. 
  363.  S. Kudrimoti1, R. Eisenberg2, G. A. Maylin3, Charlie Hughes1, and T. Tobin1*  Synthesis and characterization of 4-hydroxyxylazine and 4-hydroxyxylazine-d6 standards for use in xylazine regulation in competition horses:  Presented at the 20th International Conference of Racing Analysts and Veterinarians, Sugar Beach, Mauritius, September 2014.
  364. R. Eisenberg1, S. Kudrimoti2, C. G. Hughes2, G. A. Maylin3, and T. Tobin2* Dihydromethylprednisone, an isomeric metabolite of methylprednisolone: synthesis of an analytical standard. Presented at the 20th International Conference of Racing Analysts and Veterinarians, Sugar Beach, Mauritius, September 2014.
  365.  S. Kudrimoti1, R. Eisenberg2, G. A. Maylin3, C.G. Hughes1and T. Tobin1* 20-Dihydroprednisone: Synthesis of an isomeric equine metabolite of prednisolone for use as an analytical standard;  Presented at the 20th International Conference of Racing Analysts and Veterinarians, Sugar beach, Mauritius, September 2014.
  366. K. Brewer1, C. R. Harden2, C.G. Hughes3 and T. Tobin3 “Shipping-in,” a risk factor associated with fatal musculoskeletal racing injuries: Presented at the 20th International Conference of Racing Analysts and Veterinarians, Sugar Beach, Mauritius, September 2014.
  367. A.M. Briceño1*, A.M. Sanchez1, R.H. Galley2, K. Brewer3, C. Hughes4, T. Tobin4 Increased Incidence of Sudden Death Associated with Exercise Induced Pulmonary Hemorrhage (EIPH) in Horses Racing at Higher Altitude in Venezuela:  Presented at the 20th International Conference of Racing Analysts and Veterinarians, Sugar beach, Mauritius, September 2014.
  368. Fenger, C. K.a, Tobin, Tab, Casey, P. J.c, Roualdes, E.D, Langemeier, J. L.a, and Haines, D.M.  Supplementation Improves Earnings, Performance and Recovery in Racing Thoroughbreds Bovine Colostrum Presented at the 20th International Conference of Racing Analysts and Veterinarians, Sugar Beach, Mauritius, September 2014.
  369. RMTC Board of Directors Meeting, Canterbury Downs, Oct. 13th  2014: attendance as alternate National Horsemen’s Benevolent and Protective Association and brief presentation to the Racing Medication and Testing Consortium,[RMTC],  Minneapolis Minnesota, meeting attended on behalf of the National HBPA.
  370. Presentation to Azam Syed, Pharmacy in Charge, Zabeel Palace, Dubai and visits to and presentations to the Marmoom Equine Research Center, Dubai UAE,  December 3-14th  2014.
  371. National HBPA Winter meeting, Careferee, Arizona, Thursday, February 7th,  2015  Thomas Tobin, Kimberly Brewer and Charlie Hughes “Cobalt, Lasix, Thresholds and Withdrawal Times; An Overview”  Presentation to HBPA Winter Meeting audience as part of a panel discussion on Cobalt and Lasix and associated panel discussion. 
  372. Mumbai,  India,  Royal Western India Turf Club, Mumbai, Feb. 27th, 2015 “Where did that positive come from? Highly sensitive testing: Let me count the ways”, Thomas Tobin, Kimberly Brewer, Kent Stirling and Charlie Hughes. Travel arrangements made for live presentation at RWITC seminar but visa problems restricted presentation to Skype video format Feb. 27th, 2015. 
  373. Presentation to Azam Syed, Pharmacy in Charge, Zabeel Palace, Dubai and visits and presentations to the Marmoom Equine Research Center, Dubai UAE,  March 26th 2015.
  374. Association of Racing Commissioners International, Scientific Advisory Committee Meeting. Regulatory thresholds for Cobalt and Gamma Amino Butyric Acid [GABA] Committee meeting, T. Tobin and ARCI SAC Committee Members,  Tuesday April 21st presentation on GABA to ARCI 10 AM Thursday  April 25th 2015 Tampa, Florida. 
  375.  NorthWest Naturopathic Physicians Convention, Seattle Washington, May 2-3rd, 21015
    Patrick J. Casey, DM Gerbracht, ZJ Champion, RL Decker, R., Waling and T. Tobin; “The Role of Chaperone Proteins in Ageing and Onset of Disease in Modern Medicine”, Presentation and Publication,      
  376. Presentation to the Union Nacional de Asociaciones Ganaderas Colombianas- UNAGA, Bogota  Colombia “ T Tobin: Where did that positive  come from: Highly sensitive testing; Let me count the ways” Wednesday July 15th, 2015.
  377. National HBPA Summer Meeting, Denver, Colorado, Saturday, August 8th,  2015:  Glenys K. Noble, Kimberly Brewer, MaryAnn O’Connell, K. H. Stirling, A. Morales Briceno, J. Machin, and C. Hughes. T. Tobin: “Revisiting the Racing Medication and Testing Consortium [RMTC] Xylazine Guidelines, with Australian Assistance;  Presentation to the Summer 2015 Medication Forum of the  National Horsemen’s Benevolent and Protective Association Meeting, Denver, Colorado, Saturday, August 8th 2015.
  378. K. Brewer, J. Machin, K. Stirling, Abelardo Morales Briceno, C. Hughes and T. Tobin.  Canadian Environmental Methamphetamines Identifications Linked to a Horse Trailer:  Presentation to the Summer  2015 Medication Forum of the National Horsemen’s Benevolent and Protective Association Meeting, Denver, Colorado, Saturday, August 8th 2015.
  379. A. Morales, A. Méndez, M. Armas, C. Guarino, M. Moya, E. Suniaga, K. Brewer, T. Tobin. 2.2 Título del Trabajo: Efecto de la terapéutica combinada Levotiroxina-Clembuterol en ratones Balb/c y ratas Sprague-Dawley. 2.3 Nombre del Congreso (entidad patrocinante): 76 Aniversario del Instituto Nacional de Higiene Rafael Rangel y 37 Jornadas Científicas 2.4 Fecha: Noviembre, 2014. 2.5 Ciudad y País: Caracas, Venezuela.
  380. A. Morales, A. Méndez, M. Armas, C. Guarino, M. Moya, E. Suniaga, K. Brewer, T. Tobin. 3.2 Título del Trabajo: Efecto de la terapéutica combinada Levotiroxina-Clembuterol sobre la arteria aorta en ratones Balb/c. 3.3 Nombre del Congreso (entidad patrocinante): 76 Aniversario del Instituto Nacional de Higiene Rafael Rangel y 37 Jornadas Científicas 3.4 Fecha: Noviembre, 2014. 3.5 Ciudad y País: Caracas, Venezuela.
  381. A. Morales, A. Mendez, M. Armas, C. Guarino, M. Moya, E. Suniaga, K. Brewer, T. Tobin. 4.2 Título del Trabajo: Efecto de la levotiroxina-clembuterol sobre la arteria aorta en ratas Sprague Dawley. 4.3 Nombre del Congreso (entidad patrocinante): XXIII Jornadas Científicas Dr. Francisco de Venanzi, Instituto de Medicina Experimental Dr. José Gregorio Hernández. 4.4 Fecha: Noviembre, 2014. 4.5 Ciudad y País: Caracas, Venezuela.
  382.  Presentation to Azam Syed, Pharmacy in Charge, Zabeel Palace, Dubai and visits and presentations to the Marmoom Equine Research Center, Dubai UAE,  December 5th  2015.
  383. T. Tobin, Invited presentation to the Open Meeting of the International Group of Specialist Racing Veterinarians [IGSRV] Sha Tin, Hong Kong, December 14th, 2015 on the matter of “Managing a rash of ‘positives’ that result from a known source(s) of contamination through no fault of the trainer/owner? Is there a way to pragmatically manage positives that result from inadvertent contamination that could reasonably be expected not to have an influence on a horses’ performance?”  Abbreviated presentation because of IGSRV concerns that the Royal Western India Turf Club [RWITC] hearing on such a matter had not finalized.
  384. Tobin T, Invited presentation to the National Horsemen’s Benevolent and Protective Association, Winter Convention, Clearwater, Florida, “Inconsequential Trace Level Identifications of Environmental Substances”  K. H. Stirling, K. Brewer, MaryAnn O’Connell, A. Morales Briceno, J. Machin and T. Tobin. February 3-6-7th, 2016.
  385. Tobin T and Morales A,  DETECCION DE SUBSTANCIAS PROHIBIDAS Y SUS CONSECUENCIAS PARA INDUSTRIA HIPICA A.Morales1, A. Méndez1, K. Brewer2, C. Hughes3, T. Tobin, Congreso de Veterinaria y Ciencia y Tecnología de los Alimentos Cordoba, Spain, February 12th, 2016   
  386. CATHINONE: A Human Recreational Substance  Identified in Post-Race Urines Presentation to Azam Syed, Pharmacy in Charge, Zabeel Palace, Dubai and The A Team, Jake Machin, Kimberly Brewer, Sucheta Kudrimoti,  Kent H. Stirling, Rodney Eisenberg and Thomas Tobin Marmoom Equine Research Center, Marmoom,  Dubai UAE, Wednesday, April 6th  2016.
  387. “EQUINE MEDICATION TESTING: 100 YEAR AND STILL LEARNING” Thomas Tobin, ShivaKumar Gudlawar, Jake Machin, Kimberly Brewer, Sucheta Kudrimoti,, Rodney Eisenberg and Kent H. Stirling The Maxwell H. Gluck Equine Research Center, University of Kentucky, The Marmoom Equine Research Center, Marmoom, Dubai, UAE, The Florida Horsemen’s Benevolent and Protective Association; Presented to The Anti-Doping Laboratory Qatar [ADLQ] Annual Meeting entitled “ANTI-DOPING IN HUMANS AND ANIMALS: PARALLELS AND DIVERGENCES” in conjunction with the World Anti-Doping Association [WADA] at the Doha Marriott Hotel, Qatar, Wednesday, June 1th 2016.
  388. INVITED CHAIR, SYMPOSIUM CLOSING SESSION PANEL DISCUSSION, The Anti-Doping Laboratory Qatar [ADLQ] Annual Meeting in conjunction with the World Anti-Doping Association [WADA] entitled “ANTI-DOPING IN HUMANS AND ANIMALS: PARALLELS AND DIVERGENCES” at the Doha Marriott Hotel, Qatar, Wednesday, June 1th 2016.
  389. Jake Machin, Kimberly Brewer, Thomas Tobin, “MATTER OF DURING OR POST COLLECTION CONTAMINATION: AN OVERVIEW OF SOME CASES”  National Horsemen’s Benevolent and Protective Association, Summer Convention, Vancouver, Canada,  July 16th   2016.
  390. Kevin Kersh, DVM, DACVS; Scott R. McClure, DVM, PhD, DACVS, DACVSMR; Jake Machin, MS; Levent Dirikolu, PhD; Brad Brown, DVM; Clara Fenger, DVM, PhD, DACVIM; George Maylin, DVM, PhD; Edward Roualdes, PhD; Thomas Tobin, MRCVS, PhD, DABT Determining viable withdrawal times for dexamethasone in horses in a racing environment, where self-contamination is likely:  Clinical Guidelines for application in a regulatory environment.  Accepted for presentation  and publication at the 21st International Conference of Racing Analysts and Veterinarians, Montevideo, Uruguay, October 15-22nd, 2016.
  391. Abelardo Morales Briceño1,, Aniceto Mendez Sanchez1, Kimberly Brewer2,Thomas Tobin3 FOREIGN SUBSTANCES IDENTIFIED POST RACE IN THOROUGHBREDS AT LA RINCONADA RACETRACK, CARACAS VENEZUELA, A CLINICAL PATHOLOGICAL AND TOXICOLOGICAL STUDY. Accepted for presentation  and publication at the 21st International Conference of Racing Analysts and Veterinarians, Montevideo, Uruguay, October 15-22nd, 2016.
  392. Abelardo Morales Briceño1,2, Antonio Lamprea Garrido2, Alicia Garcia Hermoso2, Aniceto Mendez Sanchez1, Kimberly Brewer3,Thomas Tobin5 EPISTAXIS IN UNMEDICATED EQUINE DURING INTENSE EXERCISE IN ALMONTE-HUELVA-SPAIN. A PRELIMINARY REPORT: Accepted for presentation  and publication at the 21st International Conference of Racing Analysts and Veterinarians, Montevideo, Uruguay, October 15-22nd, 2016.
  393. Thomas Tobin* 1 Jake Machin1,  Sucheta Kudrimoti1 and Rodney Eisenberg2  Synthesis and Certification of a Deuterated Internal Standard for Xylazine: Accepted for presentation  and publication at the 21st International Conference of Racing Analysts and Veterinarians, Montevideo, Uruguay, October 15-22nd, 2016.
  394. Thomas Tobin, Presentation to a Joint Committee of the Louisiana Veterinary Medical Association Equine Group and the Louisiana State Racing Commission, “Optimal approaches to Regulation of Therapeutic Medications, Endogenous, Dietary and Environmental Substances” Sunday November 20th, 2016, Fairgrounds Race Track, New Orleans, Louisiana.  
  395.  Thomas Tobin and colleagues,  January 22, 2017:  1:00 p.m. - 5:00 p.m. the TEX CAUTHEN MEMORIAL SEMINAR with Dr. David Horohov,  Doug, Kerry & Steve Cauthen, Mr. Hans Albrecht, Mr. Steve Simon, Dr. Simon Curtis, FWCF,  Mr. Michael Savoldi, Dr. Pedro De Pedro and Dr. Thomas Tobin,  The Maxwell H. Gluck Equine Research Center,  University of Kentucky, Lexington, KY 40546-0099. The entire seminar was videotaped and made available on The Maxwell H. Gluck Equine Research Center web site and republished by the American Farriers Association Communications Committee on their internet newsletter / eblast.
  396.  Thomas Tobin, Friday February 3rd 2107, Seminar and round  table discussion on “Hair testing as a regulatory procedure in racing horses” , invited to participate  by the Oklahoma Horsemen’s Benevolent and Protective Association.  
  397. Thomas Tobin:  Educational presentation the on behalf of Mr. Mark Ford and the New Jersey Harness Horsemen’s Association on the matter of  appropriate blood testing sampling procedures for the regulatory control of  furosemide as first outlined in the “Furosemide in the Horse: its actions effects and regulatory control” A Testing Integrity Program Seminar held at The New Orleans Hilton Riverside, March 1 1998.  Wind Publications, PO Box 54248, Lexington Kentucky, 40524 (wind@wind.org)   
  398. Thomas Tobin, Jake Machin, Kimberly Brewer, Clara Fenger  and Thomas Tobin.   EQUINE HAIR TESTING WITH REFERENCE TO POST-RACE AND OUT OF COMPETITION TESTING: AN OVERVIEW  Presented at the National HBPA Annual Convention,  Las Vegas, Nevada , March 8-10th, 2017.  
  399. Travel to and attendance at the 2017 Dubai World Cup as a guest of hid Highness Sheikh Mohammed Bin rashid al masktoum, rand presentation to Mr. Azam Syed, Pharmacy in Charge, Zabeel Palace, Dubai and visits and presentations to the Buhoot Equine Research Center, Marmoon, Dubai, UAE,  March 22-April December 5th  2015.
  400. Educational presentation on behalf of Charles Town HBPA, May 12th 2017, THE CHARLES TOWN NAPROXEN IDENTIFICATIONS: REGIONAL HISTORIC REGULATORY THRESHOLDS AND AN INTERIM SCREENING LIMIT OF DETECTION, Submitted  by  The National HBPA, Lexington, Kentucky and Ms. Maria Catignani, The Charles Town HBPA, Charles Town, West Virginia, and Mr. Jake Machin, BSc, and Thomas Tobin, MVB, MRCVS, PhD, Rm128c, The Maxwell H. Gluck Equine Research Center, 1400 Nicholasville Rd, University of Kentucky, Lexington, Kentucky 40546-0099, and Dr. Kimberly Brewer DVM, MSc, 1711 Lakefield North Court, Wellington, Florida 33414